Zydus Lifesciences International Markets Head Change

Nature of change: Resignation and new appointment

Resignation Details:

Dr. Amrut Naik has resigned from his position as President and Business Unit Head, International Markets Business
Date of resignation: October 31, 2026
Effective relief date: November 7, 2026
He will cease to be part of the Senior Management team
Resignation reason: Personal decision (not specified in detail)

Appointment Details:

Mr. Christoph Stoller appointed as President and Business Unit Head, International Markets Business
Date of appointment: November 2, 2026
Term of appointment: Full-time employment
Appointment approved by Board of Directors based on recommendation of Nomination and Remuneration Committee
He will be part of the Senior Management team

Brief profile of Mr. Christoph Stoller:

Swiss pharmaceutical industry leader with more than 30 years of global experience
Educational qualification: Degree in Business Administration, Economics, Law, and Social Sciences from University of St. Gallen, Switzerland
Previous role: President & Business Head (EMEA, LATAM & APAC) at Glenmark Pharmaceuticals
Member of Glenmark's Global Leadership Team
Led approximately 2,000 employees across 80 countries
P&L responsibility exceeding USD 750 million
Major career achievements: Doubled European revenue at Glenmark from approximately USD 200 million and significantly improved EBITDA performance

Previous leadership roles:

Teva Pharmaceuticals (2011-2021): Senior Vice President & Cluster General Manager, Germany & Austria; Senior Vice President, Generics & Commercial Operations Europe
Managed businesses with up to USD 2 billion P&L and around 2,700 employees
Led European integration of Teva's acquisition of Actavis
Helvepharm AG: CEO and member of Executive Committee of Zur Rose Group
Earlier career: Leadership roles at Roche Pharma, DSM Nutritional Products, and Swiss Re

Industry Leadership & Governance:

Former President of Medicines for Europe (2019-2021), the leading European association representing generic and biosimilar medicine companies
Held Vice President and Executive Committee positions within Medicines for Europe
Former Vice Chairman of Progenerika (Germany) and Board Member of Intergenerika (Switzerland)

Regulatory Compliance:

Disclosure made under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Compliance with SEBI Master Circular dated January 30, 2026
Signed by Dhaval N. Soni, Company Secretary and Compliance Officer (Membership No. FCS7063)

No financial or operational approvals disclosed in this filing beyond the management change.

No specific business outlook, strategic context, or operational updates provided in this disclosure beyond the management change details.

The company confirmed compliance with all necessary disclosure requirements under SEBI Listing Regulations
All required annexures and documentation have been provided as per regulatory requirements
Digital signatures and proper authorization confirmed for all documents